Featured Research

from universities, journals, and other organizations

New Guideline For Treating Lyme Disease

Date:
May 25, 2007
Source:
American Academy of Neurology
Summary:
A guideline developed by the American Academy of Neurology finds conventionally recommended courses of antibiotics are highly effective for treating nervous system Lyme disease. However, there is no compelling evidence that prolonged treatment with antibiotics has any benefit in treating symptoms that persist following standard therapy.

A guideline developed by the American Academy of Neurology finds conventionally recommended courses of antibiotics are highly effective for treating nervous system Lyme disease. However, there is no compelling evidence that prolonged treatment with antibiotics has any benefit in treating symptoms that persist following standard therapy. 

Lyme disease, an infectious disease caused by tick-borne bacteria, affects the nervous system in 10 to 15 percent of infected patients.

"While other guidelines exist to help diagnose and treat general Lyme disease, there continues to be considerable controversy and uncertainty about the best approach to treating neuroborreliosis, in which Lyme disease involves the nervous system," said lead guideline author John J. Halperin, MD, with Atlantic Health in Summit, NJ, and Fellow of the American Academy of Neurology.

To develop the guideline, the authors analyzed all available scientific studies on the topic.

The evidence shows that using antibiotics for two to four weeks is highly effective for treating neuroborreliosis. Lyme disease responds well to the intravenous antibiotics penicillin, ceftriaxone, cefotaxime, and oral doxycycline, and these antibiotics are probably safe and effective when taken for 14 to 28 days by children and adults.

Halperin says other oral antibiotics, such as amoxicillin and cefuroxime axetil, may be alternative treatment options for Lyme disease, but there is not enough supporting evidence to recommend them.

Patients who have received accepted antibiotic regimens for Lyme disease sometimes have persisting symptoms, often referred to as Post-Lyme syndrome (PLS). This guideline states that long-term use of antibiotics does not improve the outcome in people with chronic symptoms after customary treatment of Lyme disease. Specifically, further treatment does not improve overall health quality of life, memory, or depression. Long-term antibiotic use can be associated with such side effects as diarrhea, blood stream infections, and blood clots.

"While it is clear from all available scientific studies that long-term use of antibiotics doesn't help to treat chronic symptoms that persist after treatment for Lyme disease, the symptom complex will remain problematic until we can better understand the cause of these symptoms and find appropriate treatments," said Halperin.

The guideline is published May 23, 2007, in the online edition of Neurology®, the scientific journal of the American Academy of Neurology.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "New Guideline For Treating Lyme Disease." ScienceDaily. ScienceDaily, 25 May 2007. <www.sciencedaily.com/releases/2007/05/070523163057.htm>.
American Academy of Neurology. (2007, May 25). New Guideline For Treating Lyme Disease. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/05/070523163057.htm
American Academy of Neurology. "New Guideline For Treating Lyme Disease." ScienceDaily. www.sciencedaily.com/releases/2007/05/070523163057.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins